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Heterologous prime-boost vaccination with H3N2 inﬂuenza
viruses of swine favors cross-clade antibody responses and
protection
Kristien Van Reeth1, José Carlos Mancera Gracia1, Ivan Trus 1, Lieve Sys1, Gerwin Claes1, Han Versnaeyen2, Eric Cox3,
Florian Krammer4 and Yu Qiu5
The emergence of multiple novel lineages of H1 and H3 inﬂuenza A viruses in swine has confounded control by inactivated
vaccines. Because of substantial genetic and geographic heterogeneity among circulating swine inﬂuenza viruses, one vaccine
strain per subtype cannot be efﬁcacious against all of the current lineages. We have performed vaccination-challenge studies in
pigs to examine whether priming and booster vaccinations with antigenically distinct H3N2 swine inﬂuenza viruses could broaden
antibody responses and protection. We prepared monovalent whole inactivated, adjuvanted vaccines based on a European and a
North American H3N2 swine inﬂuenza virus, which showed 81.5% aa homology in the HA1 region of the hemagglutinin and 83.4%
in the neuraminidase. Our data show that (i) Priming with European and boosting with North American H3N2 swine inﬂuenza virus
induces antibodies and protection against both vaccine strains, unlike prime-boost vaccination with a single virus or a single
administration of bivalent vaccine. (ii) The heterologous prime-boost vaccination enhances hemagglutination inhibiting, virus
neutralizing and neuraminidase inhibiting antibody responses against H3N2 viruses that are antigenically distinct from both
vaccine strains. Antibody titers to the most divergent viruses were higher than after two administrations of bivalent vaccine. (iii)
However, it does not induce antibodies to the conserved hemagglutinin stalk or to other hemagglutinin subtypes. We conclude
that heterologous prime-boost vaccination might broaden protection to H3N2 swine inﬂuenza viruses and reduce the total amount
of vaccine needed. This strategy holds potential for vaccination against inﬂuenza viruses from both humans and swine and for a
better control of (reverse) zoonotic transmission of inﬂuenza viruses.
npj Vaccines  (2017) 2:11 ; doi:10.1038/s41541-017-0012-x
INTRODUCTION
Inactivated inﬂuenza vaccines protect by inducing serum antibody
against the hemagglutinin (HA) and, to a lesser degree, the
neuraminidase (NA) of the vaccine strains. While the HA is highly
immunogenic and the target for neutralizing antibodies, it is also
the most variable protein. For this reason, human inﬂuenza
vaccine strains are updated every few years.1 Inﬂuenza A viruses of
H1N1, H3N2, and H1N2 subtypes are enzootic in swine worldwide2
and both the viruses and the inactivated vaccines for swine
resemble those of humans. However, while the human vaccines
generally contain puriﬁed viral surface antigens without adjuvant,
swine inﬂuenza virus (SIV) vaccines are mostly whole virus
preparations with an oil-based adjuvant. Also, there is no formal
system to recommend vaccine strains for swine and SIV vaccine
strains are only rarely updated.3 This is in part due to slower
antigenic drift of inﬂuenza viruses in swine than in humans4, 5 and
to regulatory and economic constraints. Some commercial oil-
adjuvanted SIV vaccines have been shown to protect against SIVs
isolated decades after the introduction of the vaccine and with
considerable antigenic changes.3, 6 On the other hand, multiple
novel antigenically distinct H1 and H3 SIV lineages have emerged
during the last 20 years2, 5, 7 and they are now co-circulating in
many regions. The prevailing lineages also differ between
continents and regions, and SIV vaccines for Europe and North
America are produced locally and they contain completely
different strains.3 Thus, it is unlikely that one strain per subtype
would be efﬁcacious globally or within a given region.
All known H3N2 SIVs have HA and NA proteins derived from
viruses that once circulated in the human population.2, 8 Shortly
after the Hong Kong inﬂuenza pandemic in 1968, human-like
H3N2 inﬂuenza viruses were isolated from European pigs.2 In the
US swine population, three separate introductions of A/Nanchang/
95-like human H3N2 viruses occurred between 1995 and 1997,
leading to three antigenic clusters (I, II, III) in swine.2 The now
dominant cluster IV has evolved from cluster III around 20059 and
is mostly found with a more recent human N2 from around 2002,
though some viruses still have the original N2 from 1995 strains.10
On both continents, the internal genes of the human seasonal
H3N2 viruses have been replaced with those of viruses that were
likely better adapted for replication in swine by reassortment. This
has led to the designation “triple-reassortant” SIV in North
America, because of a ﬁxed combination of internal genes of
human, avian, and swine virus origin.9 More recently the 2009
pandemic H1N1 virus has reassorted extensively with the
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previously established SIVs.7, 10 One of many novel genotypes, a
triple reassortant H3N2 SIV in which only the matrix gene comes
from the 2009 pandemic virus, has infected over 350 humans
since 2011.9 This virus is also known as H3N2 “variant” or H3N2“v”,
a designation used for SIVs that are isolated from humans. Since
2012, H3N2 and H3N1 viruses with an HA from human strains from
the 2010–2011 season have also been reported in swine in the
US.11 Thus, the frequent introduction of human H3N2 viruses and
the geographic separation of the swine population have led to
considerable diversity in SIVs in different regions. Swine H3N2
viruses are also no longer similar to the current human H3N2
viruses because of a different evolution in swine vs. humans.
Swine can act as reservoirs for older human HAs and several
studies have shown a lack of protective serum antibody titers
against H3N2 SIVs in people born after the circulation of the
respective human precursor viruses.12–14 SIVs therefore pose a
threat for reintroduction into the human population once
immunity has waned sufﬁciently to allow widespread infection.
Inﬂuenza naïve humans or pigs need two doses of killed
inﬂuenza vaccine, 3 or 4 weeks apart, to achieve a satisfactory
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Fig. 1 Heterologous prime-boost vaccination with G08 and PA10 induces antibodies against both vaccine strains. Serum antibody titers are
compared with those achieved by homologous prime-boost vaccination and one or two administrations of bivalent vaccine. The time interval
between the priming (1°) and booster (2°) immunizations was 4 weeks. HI (a, d), VN (b, e) and NI (c, f) antibody titers were determined at 4
timepoints: before the priming vaccination, 4 weeks after the priming vaccination and before the booster vaccination, and 2 and 4 weeks after
the booster vaccination (weeks 0, 4, 6, and 8). The vaccine groups are grouped along the x-axis. The bivalent vaccine (1x) group received a
single vaccine administration at week 4 of the experiment. Geometric mean antibody titers against G08 and PA10 are shown in ﬁgures a–c and
d–f respectively. Error bars represent SD. Dotted lines indicate limits of detection. Pigs of the mock-vaccinated control group (not shown) had
no detectable antibody titers in all three assays. Asterisks denote signiﬁcant differences between the heterologous prime-boost and other
groups in the Kruskal-Wallis test. *P< 0.05; **P< 0.01; ***P< 0.001
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level of antibody on primary immunization. One approach to
broaden the immune response is to use antigens from divergent
virus strains for primary and booster vaccinations. This has been
documented in vaccination experiments with avian H5N1
inﬂuenza viruses in poultry15 and in humans,16, 17 and with
human H1N1 and H3N2 viruses in the mouse and ferret model.18–
20 In 2009, vaccination with the novel pandemic H1N1 virus
resulted in a broad, pan-H1 neutralizing antibody response in
people who had been exposed to human seasonal H1N1 viruses
from 1977–2008, despite a lack of serological cross-reactivity
between these H1N1 viruses.21 Here we aimed to examine
whether primary and booster vaccinations with antigenically
distinct European and North American H3N2 SIVs could broaden
antibody responses and protection in swine.
RESULTS
Heterologous prime-boost vaccination with European and North
American H3N2 SIVs induces antibody titers against both vaccine
strains
We prepared adjuvanted inactivated, monovalent whole virus
vaccines based on contemporary European (sw/Gent/172/2008,
G08) and North American (sw/Pennsylvania/A01076777/2010,
PA10) H3N2 SIVs. These strains show low amino acid (aa)
homology in the HA1 subunit (81.5%) of the HA and in the NA
(83.4%), and as many as 20 aa differences at putative antigenic
sites of the HA1 (Figs. S1,2) and NA on a total of 40 and 34 aa
residues, respectively.11, 22–24
Pigs were injected ﬁrst with G08 vaccine and boosted 4 weeks
later with PA10 vaccine (heterologous prime-boost group) or
primed and boosted with identical virus strains, either G08 or
PA10 (homologous prime-boost groups). We also included pigs
that received a single (bivalent vaccine 1x group) or two
consecutive administrations (bivalent vaccine 2x group) of a
combination vaccine containing both strains, or two administra-
tions of mock vaccine.
We ﬁrst examined the evolution of antibody titers against both
vaccine strains by hemagglutination inhibition (HI), virus neutra-
lization (VN) and neuraminidase inhibition (NI). Sera from mock-
vaccinated control pigs and prevaccination sera tested negative in
all three assays. Postvaccination antibody titers were higher in the
VN than in HI or NI assays, but the three assays revealed a similar
pattern (Fig. 1a–f). After a single administration of monovalent or
bivalent vaccine most pigs had minimal or low antibody titers
against the virus(es) in the vaccine. Data at week 6 and 8
demonstrate the effect of the booster vaccination. Priming and
boosting with identical virus strains induced high antibody titers
against the vaccine strain only, which were comparable in both
groups, but minimal titers to the heterologous virus. The
heterologous prime-boost group, in contrast, mounted solid HI,
VN, and NI antibody titers against both vaccine strains, which did
not differ signiﬁcantly from those in the homologous prime-boost
groups (P≥ 0.3416). Anti-G08 titers were signiﬁcantly higher in the
heterologous prime-boost group than in the bivalent vaccine (1x)
group, but there were no signiﬁcant differences in anti-PA10 titers,
except for HI titers at week 8. This can be explained by the higher
antibody titers against G08 than against PA10 upon the
heterologous boost. Importantly, antibody titers against both
vaccine strains were comparable in the heterologous prime-boost
and bivalent vaccine (2x) groups (P≥ 0.9999) (Table S1).
We also wanted to compare the frequency of vaccine-speciﬁc
antibody secreting cells (ASC) between groups. To this purpose we
collected peripheral blood mononuclear cells (PBMC) from four
pigs of each group, except for the bivalent vaccine (2x) group, just
before the booster or single vaccination and 7 days later. These
timepoints were selected because ASC responses have been
shown to peak 1 week after immunization of primed subjects.21
Numbers of IgG secreting PBMC were determined in an ELISPOT
assay, using either one of both vaccine strains as stimuli, as well as
the H3N2v virus A/Indiana/08/2011 (IN11). Virus-speciﬁc ASC were
undetectable in all pigs at the time of vaccination, and 7 days later
in the mock-vaccinated control and bivalent vaccine (1x) groups
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Fig. 2 Higher numbers of vaccine-speciﬁc antibody secreting cells
(ASC) in pigs of the heterologous prime-boost group as compared
to homologous prime-boost and bivalent vaccine (1x) groups.
Peripheral blood mononuclear cells of four pigs per group were
collected at the time of the booster or single vaccination and 7 days
later. Numbers of IgG ASC were determined by direct ELISPOT
against three viruses: the vaccine strains G08 (a) and PA10 (b) and
the H3N2v virus A/Indiana/08/2011 (IN11, c), which is related to
PA10. Virus-speciﬁc responses were undetectable at the time of
vaccination, results 7 days postvaccination are shown. Each data
point represents an individual pig, horizontal lines indicate group
means. Numbers of virus-speciﬁc ASC against all three virus strains
were higher in pigs from the heterologous prime-boost group as
compared to the mock-vaccinated control and bivalent vaccine (1x)
groups (P< 0.01, Kruskal-Wallis test), and the G08 and PA10
homologous prime-boost groups (P> 0.05)
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(Fig. 2a–c). The homologous boost with PA10 resulted in ASC
reacting with the vaccine virus and the related IN11 virus (Fig. 2b,
c). Both homologous prime-boost groups had minimal responses
to G08 (Fig. 2a). The heterologous prime-boost group showed
increased numbers of ASC against all three viruses. Two of the four
pigs in this group had substantially higher responses than the
PA10 homologous prime-boost group. However, the differences
between vaccine groups were not statistically signiﬁcant (P > 0.05)
because of a large degree of inter-animal variability.
These results suggest that the humoral immunity induced by
G08 vaccine primes pigs for stronger responses to both vaccine
viruses on subsequent vaccination with PA10.
Heterologous prime-boost vaccination with G08 and PA10
protects against challenge with either one of both vaccine strains
The next step was to demonstrate the extent of protection against
challenge with the vaccine strains. Though SIVs replicate
throughout the respiratory tract of pigs, the lungs are the major
target and lung virus titers correlate with disease. Yet typical
clinical signs can only be reproduced by direct intratracheal
inoculation of a high virus dose, which is artiﬁcial and results in
delayed virus replication in the upper airways.3, 6 We therefore
chose to inoculate the pigs intranasally and to determine virus
titers in the lung, trachea and nasal mucosa.
Both G08 and PA10 replicated to high titers in all samples of the
challenge control pigs (Fig. 3a, b). Homologous prime-boost
vaccination with G08 or PA10 offered a complete protection
against replication of the homologous challenge virus, except for
one or two samples of the nasal mucosa. Protection against
heterologous challenge, in contrast, was lacking. Heterologous
prime-boost vaccination protected completely against challenge
with G08, except for three tracheal samples (P < 0.01 for all pigs).
After challenge with PA10, most pigs did not have detectable virus
in the lungs and trachea, and mean virus titers were signiﬁcantly
reduced (P < 0.001 for lungs and nasal mucosa, P < 0.01 for
trachea). One administration of bivalent vaccine resulted in an
inferior protection against both viruses. In the bivalent vaccine (2x)
pigs virus was recovered from the nasal mucosa only in one (G08)
or both pigs (PA10).
Intranasal inoculation of pigs with SIV causes only mild lesions
of the respiratory tract. However, enhanced lesions as compared
to those in unvaccinated challenge controls had been reported in
pigs vaccinated with adjuvanted inactivated vaccine followed by
challenge with a homosubtypic but antigenically distinct SIV.25
This has prompted us to perform (histo)pathological examinations
of the lungs and trachea. Unvaccinated, unchallenged control
pigs, which tested negative for SIV and antibodies until the end of
the study, did not show gross lung lesions or microscopic lesions
of the trachea. Lung epithelial damage and peribronchiolar
lymphocytic cufﬁng were occasionally seen. Only part of the
mock-vaccinated challenge control pigs showed macroscopic lung
lesions, involving ≤10% of the lungs, after challenge with G08 or
PA10 (Table S2). Microscopic lesions were also mild and consisted
of accumulations of lymphocytes and neutrophils in or around
bronchioli, bronchiolar epithelial damage, thickening of the
alveolar walls and focal attenuation of the tracheal epithelium
(Table S2, Fig. S3).
The vaccinated pigs also had no or minimal macroscopic
pneumonia, and mild microscopic lesions. Compared to the
challenge control groups, most vaccinated groups had milder
microscopic lesion scores. This was most prominent for the
bivalent vaccine (2x) groups and the homologous prime-boost
groups challenged with homologous virus, but none of the
differences between vaccinated and control groups were statis-
tically signiﬁcant (P = 0.06–1.00, Kruskal-Wallis; P = 0.08–1.00, two-
sided Fisher’s exact test). We found only moderate correlations
between lesion scores and viral loads in the lungs or trachea of
individual pigs (Spearman’s rho = 0.37 and 0.59, P < 0.01). Most
important, none of the vaccine groups showed evidence of
enhanced lesions relative to the challenge control.
Heterologous prime-boost vaccination enhances serological cross-
reactivity with H3N2 viruses that are antigenically distinct from
both vaccine strains
To further analyse the breadth of the antibody response, we
examined sera collected 2 weeks after the booster vaccination for
their cross-reactivity with heterologous H3N2 or H1N2 SIVs and
human seasonal H3N2 viruses of different antigenic clusters
(Tables 1, 2). A/Victoria/3/1975 and A/Nanchang/933/1995 are the
*
G08 challenge
6 66
6 6
1 0 0 0 0
66
666
0 00 0
3
66 6 5
5
***
***
**
1
0 0 0 0
***
**
n=6 n=5 n=6 n=7 n=6 n=2
***
***
**
0
2
4
6
8
10
0
2
4
6
8
10
M
e
a
n
 
v
iru
s
 ti
te
r 
(lo
g 1
0 
TC
ID
50
/g
)
M
e
a
n
 
v
iru
s
 ti
te
r 
(lo
g 1
0 
TC
ID
50
/g
) PA10 challenge
44
4
4
6
6
2
3
2 2
20 0 0 0
66 66 6 6
6
66 6
A
B
***
**
Lung accessory lobe
Nasal mucosa Trachea Lung right
Lung left
2
0 0 0 0
**
*
***
n=6 n=6 n=5 n=7 n=6 n=2
Fig. 3 Heterologous prime-boost vaccination with G08 and PA10
protects against challenge with either one of both vaccine strains.
Pigs were challenged intranasally with 107 TCID50 of G08 (a) or PA10
(b) 1 month after the booster vaccination or after the single
vaccination in the bivalent vaccine (1x) group. They were euthanized
3 days after the challenge, and virus titers were determined in
samples of the nasal mucosa, trachea and three different parts of
the lung. Bars represent mean virus titers± SD. Dotted lines indicate
the limit of detection. Numbers along the x-axis represent the
number of pigs challenged with G08 or PA10 in each group.
Numbers on top of the bars indicate the number of pigs with
detectable viral titers. Asterisks indicate signiﬁcantly reduced virus
titers as compared to the mock-vaccinated challenge control group
in ANOVA. *P< 0.05, **P< 0.01, ***P< 0.001. The normal distribution
was assessed by the Shapiro-Wilk test. Statistically signiﬁcant
reductions of the number of virus-positive pigs were observed
upon G08 challenge in the G08 homologous prime-boost (P< 0.05
for nasal mucosa and P< 0.01 for other samples, Fisher’s exact test)
and heterologous prime-boost groups (P< 0.001, all samples except
trachea) and upon PA10 challenge in the PA10 homologous prime-
boost (P< 0.01, all samples except nasal mucosa) and heterologous
prime-boost groups (P< 0.05, all samples except nasal mucosa). A
signiﬁcant reduction was also observed in the bivalent vaccine (2x)
group for trachea and lung samples (P< 0.05)
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supposed human precursors of the European and North American
H3N2 SIV lineages respectively. The antigenic distance between
H3N2 SIVs in Europe and North America is on average 12.6
antigenic units (AU).2 The recent human H3N2 virus A/Victoria/
361/2011 is 14.9 AU away from contemporary European H3N2 SIVs
and 6.4 AU from North American H3N2 SIVs. H3N2 SIVs show
lower antigenic diversity in Europe (0.28 AU per year) than in the
US (0.49 AU per year). Though A/Indiana/08/2011, an H3N2v virus,
and sw/Iowa/A01049750/2011 are cluster IV North American H3N2
viruses, they are considered antigenically distant from PA10.4 The
average distance between consecutive human clusters is 4.5 AU.26
Human inﬂuenza vaccine strains are updated when there is an
antigenic difference of at least 2 units between the vaccine strain
and the strains expected to circulate in the next season.
The genetic relatedness between the surface proteins of the
vaccine and test viruses was in line with the ancestry of the
vaccine strains (Table 1). According to previous studies with
human and swine H3N2 viruses marked antigenic differences and
vaccine failure may result from as few as 1 or 2 substitutions at
6–7 key aa residues in antigenic sites A and B.4, 27 Most viruses
included in HI and VN assays differed from both vaccine strains in
at least 4 of these residues (Figs. S1, 2). While the HA2 was more
conserved, the NA showed a largely similar pattern as the HA1.
However, the NA of G08 and PA10 showed considerable genetic
divergence from that of sw/Gent/26/2012 (H1N2) and sw/Iowa/
A01049750/2011 (H3N2) respectively.
Mock-vaccinated control pigs tested negative against all viruses
in all three assays. The vaccinated pigs showed largely similar
antibody proﬁles in HI and VN assays, though VN titers were
usually higher (Table 2). Based on the published literature 28, 29 we
consider HI titers≥ 40 and VN titers ≥ 64 as seroprotective. The
homologous prime-boost vaccinations with G08 or PA10 induced
seroprotective antibody titers against SIVs of the same lineage as
the vaccine strains and related human seasonal H3N2 viruses, but
not to human viruses from 2005–2011. The heterologous prime-
boost group, on the other hand, developed antibodies against
both European and North American cluster IV H3N2 SIVs, though
antibody titers were generally lower than in the respective
homologous prime-boost groups. Only this group mounted solid
antibody titers against the more divergent cluster I North
American H3N2 SIVs sw/Texas/4199-2/1998 and sw/Minnesota/
593/1999. Remarkably, two administrations of bivalent vaccine
induced barely detectable antibody titers against cluster I viruses
and lower titers against some human H3N2 viruses than the
heterologous prime-boost. As expected, a single administration of
bivalent vaccine was insufﬁcient to induce seroprotective anti-
body titers.
NI assays were performed against a smaller selection of viruses
(Table 3). The homologous prime-boost vaccinations with G08 or
PA10 induced high NI titers against the respective vaccine strains
and against the related IN11 strain in the PA10 homologous
prime-boost group. Antibody titers against SIVs with an anti-
genically distinct NA were ≥10-fold lower or undetectable. After
the heterologous prime-boost vaccination, in contrast, most pigs
had substantial NI titers against both vaccine strains and the four
heterologous SIVs. Most remarkable were the high NI titers (GMT
160) against the European H1N2 SIV sw/Gent/26/2012, which
exceeded those in any other group including the bivalent vaccine
(2x) group.
Overall, the sera from the heterologous prime-boost group were
consistently the most cross-reactive in HI, VN, and NI assays (Fig.
S4).
Lack of HA-stalk and heterosubtypic antibodies after heterologous
prime-boost vaccination
The ﬁnding that VN antibody titers were several fold higher than
HI titers suggests that antibodies may be in part directed to
regions outside the receptor-binding site of the HA. We therefore
Table 1. Inﬂuenza virus strains used in serological assays and their genetic relationship with the HA and NA of both vaccine strains
% amino acid identity to
Origin of sw/Gent/2008 (G08) sw/PA/2010 (PA10)
Virus lineage Virus strain HA gene NA gene HA1 HA2 NA HA1 HA2 NA
Eu swine H3N2 Sw/Gent/1984 hu ‘73–‘75 hu ‘73–‘75 89.4 (7)* 92.3 93.7 (4) 80.5 (23) 93.2 86.5 (19)
Sw/Eng/1987 hu ‘73–‘75 hu ‘73–‘75 83.0 (11) 88.7 89.0 (7) 79.6 (20) 91.9 86.8 (17)
Sw/Gent/2008 hu ‘73–‘75 hu ‘73–‘75 100 100 100 81.5 (20) 91.0 83.4 (20)
Eu swine H1N2 Sw/Gent/2012 hu ‘80 hu ‘73–‘75 n.a. n.a. 87.0 (10) n.a. n.a. 83.8 (15)
N A swine H3N2 cluster I Sw/TX/1998 hu ‘95–‘96 hu ‘95–‘96 82.4 (19) 92.3 87.9 (14) 88.8 (13) 95.0 91.7 (11)
Sw/MN/1999 hu ‘95–‘96 hu ‘95–‘96 82.1 (20) 92.3 88.1 (13) 88.8 (13) 95.0 91.5 (12)
N A swine H3N2 cluster IV Sw/ON/2005 hu ‘95–‘96 hu ‘95–‘96 81.5 (19) 91.9 85.6 (16) 96.7 (5) 98.2 95.7 (10)
Sw/PA/2010 hu ‘95–‘96 hu ‘01–‘02 81.5 (20) 91.0 83.4 (20) 100 100 100
A/IN/2011 hu ‘95–‘96 hu ‘01–‘02 79.6 (18) 90.0 83.2 (20) 94.2 (4) 95.9 99.8 (0)
Sw/IA/2011 hu ‘95–‘96 hu ‘95–‘96 80.2 (17) 90.0 88.8 (11) 93.6 (6) 95.5 89.1 (14)
Human seasonal H3N2 A/Vict/1975 n.a. n.a. 86.6 (11) 92.3 90.9 (9) 83.6 (22) 95.0 88.7 (15)
A/Eng/1988 n.a. n.a. 85.1 (13) 92.3 89.4 (12) 90.0 (13) 95.0 90.4 (13)
A/Nanch/1995 n.a. n.a. 83.0 (17) 92.8 88.1 (13) 91.5 (12) 96.4 91.9 (12)
AWisc/2005 n.a. n.a. 80.9 (15) 91.9 86.6 (15) 86.3 (18) 95.0 91.7 (10)
A/Perth/2009 n.a. n.a. 80.5 (17) 91.4 86.0 (14) 87.6 (14) 94.1 91.3 (11)
A/Vict/2011 n.a. n.a. 80.5 (16) 91.4 84.7 (17) 86.1 (15) 94.1 91.3 (8)
HA hemagglutinin, NA neuraminidase, Eu European, N A North American, hu= human seasonal H3N2 inﬂuenza virus, n.a. not applicable *Number of aa
differences at presumed antigenic sites is indicated between brackets. Full virus names: sw/Gent/1/1984, sw/England/163266/1987, sw/Gent/172/2008, sw/
Gent/26/2012, sw/Texas/4199-2/1998, sw/Minnesota/593/1999, sw/Ontario/33853/2005, sw/Pennsylvania/A01076777/2010, A/Indiana/08/2011, sw/Iowa/
A01049750/2011, A/Victoria/3/1975, A/England/427/1988, A/Nanchang/933/1995, A/Wisconsin/67/2005, A/Perth/16/2009, A/Victoria/361/2011
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examined postvaccination sera for antibody speciﬁc for the HA
stalk by ELISA. However, while antistalk titers were measurable in
vaccinated pigs they ranged from 100 to 400 in all groups without
statistically signiﬁcant differences with the mock-vaccinated
control group (Fig. S5, P > 0.05). These titers are very low and
unlikely to mediate protection. As comparison, adult humans have
baseline titers of 1600 which are considered non-protective.30, 31
Finally, we performed HI and VN assays against avian H4 and H7
inﬂuenza viruses, which are phylogenetically closely related to H3,
as well as H1 SIVs. Heterosubtypic antibodies were detectable in
the heterologous prime-boost group only (Table S3). Low
antibody titers against H1N2 were found in two pigs by HI and
in four pigs by VN. Only one pig showed antibodies against H4N1
and H4N6 viruses. All pigs of this group were negative for
antibodies against H1N1 and H7N1 viruses.
The overall lack of heterosubtypic antibodies is consistent with
the lack of antistalk antibodies and suggests that antibodies
induced by the heterologous prime-boost vaccination primarily
target conserved epitopes in the globular head of the HA.
DISCUSSION
We have proven the concept that priming and boosting pigs with
inactivated SIVs of distinct H3N2 lineages can broaden the
immune response against both HA and NA. Broader anti-HA
antibody responses and protection have previously been reported
after sequential immunizations of humans, birds, ferrets or mice
with antigenically distinct viruses within the H1N1, H3N2 or
H5 subtype.15–20 Previous studies in pigs have shown enhanced
anti-HA antibody titers after priming with live wild-type SIVs, or HA
gene-based vaccines, and boosting with a single dose of
commercial inactivated SIV vaccine.32–34 But while the HAs of
the viruses used for both immunizations were divergent in the
studies with live virus,34 they were very similar in those with gene-
based vaccines.32, 33 The present study is also the ﬁrst to examine
antibody responses to both HA and NA of swine and human H3N2
inﬂuenza viruses from various clusters. The observed anti-N2
antibody response may even partially protect against the
European H1N2 SIV lineage, for which both surface proteins are
far distant from the co-circulating H1N1 and H3N2 SIVs. On the
other hand, our approach failed to induce antibodies against the
most recent human seasonal H3N2 viruses or other subtypes, and
it does not alleviate the need for H1 components in SIV vaccines.
This is in agreement with the minimal anti-H3 stalk antibody titers,
which appear to be essential for cross-reactivity across subtypes
and cannot be induced by whole inactivated vaccines as such.35
Based on the published literature,15, 21, 36, 37 we speculate that
sequential vaccination with G08 and PA10 induces antibodies
against shared epitopes in the HA of both viruses. The traditional
approach of using the same or very similar inﬂuenza strains for the
ﬁrst and secondary vaccinations is known to favor an isolate-
speciﬁc antibody response against highly variable, immunodomi-
nant epitopes in the globular head of the HA. Antigenically very
distinct strains within the same subtype, such as G08 and PA10,
differ from each other in most or many of these variable epitopes,
which are recognized by the majority of memory B cells induced
Table 2. Comparison of HI and VN antibody titers against heterologous H3N2 inﬂuenza viruses in pigs of different vaccine groups
Geometric mean antibody titer (no. of pigs with detectable titers)
1°, 2°: Virus strains used for ﬁrst and second vaccination; Antibody titers were determined 2 weeks after the last vaccination (day 42); See table 1 for full virus
names, *cluster I or IV HA indicated between brackets; n= number of pigs examined per group. Sera were tested at an initial dilution of 1:20 (HI) or 1:16 (VN),
those that were negative were assigned a titer of 10 (HI) or 8 (VN); Grey shade indicates titers≥ 40 in HI assay and ≥64 in VN assay, which are considered as
seroprotective. The color coding of viruses is based on the antigenic clusters of HA.2, 4, 26 Viruses of different clusters differ by at least 4 antigenic units.
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by the previous vaccination(s). It is believed that a booster
vaccination with such a distinct strain has the capacity to expand
the rare memory B cells that recognize conserved, subdominant
epitopes in the HA head or stalk.15, 21, 36, 37 Consequently, the
resulting antibodies will not only cross-react with both vaccine
strains, they will likely also be more cross-reactive against other
isolates. The overall broader serologic cross-reactivity after
heterologous prime-boosting with G08 and PA10 than after two
administrations of bivalent vaccine (Fig. S4) supports this
hypothesis. Our ELISPOT analyses of inﬂuenza-speciﬁc ASC show
limitations regarding the number of pigs, timepoints and viruses
examined. Also, the respective homologous prime-boost groups
showed higher responses to PA10 than to G08 after the booster
vaccination. We should mention here that we had unwillingly
used a slightly lower concentration of G08 than of both other test
viruses, which may have resulted in an underestimation of the
response to G08. Still, the heterologous boost led to an increase in
ASC against all three viruses examined. We cannot explain why
two pigs of the heterologous prime-boost group had higher ASC
responses than the homologous prime-boost controls without
showing higher serum antibody titers. It is possible that the
kinetics of antibody secretion differ after heterologous vs.
homologous boosting and/or that the ELISPOT detects a broader
spectrum of antibodies than the functional serological assays. Our
ﬁndings are reminiscent of the rapid and broad immune response
to a single dose of subunit 2009 pandemic H1N1 inﬂuenza vaccine
in people without detectable antibodies to this antigenically novel
virus.21 Their ASC responses peaked as early as 1 week post
vaccination and consisted mainly of IgG secreting plasmablasts
that had undergone extensive afﬁnity maturation.21, 37 This led to
the discovery of pre-existing cross-reactive memory B cells that
bind to epitopes conserved between past seasonal H1N1 strains
from 1977–2008 and the pandemic H1N1 virus, and which appear
to be most efﬁciently recalled by consecutive immunizations with
divergent virus strains. 21, 37, 38
The heterologous prime-boost vaccination offered a superior
protection against challenge with G08 as compared to PA10,
which was associated with higher anti-G08 serum antibody titers.
This raises the question as to whether the heterologous boost
favours an antibody response to the virus strain encountered ﬁrst.
A similar phenomenon exists in humans and laboratory animals
and has been called “back boosting”, “antigenic seniority” or,
initially, “original antigenic sin”.39–42 Consistent with other studies
with inactivated inﬂuenza vaccine,43 our ﬁndings do not ﬁt the
strictest deﬁnition of original antigenic sin, because there was no
impairment or true suppression of the antibody response to the
second vaccine strain. Also, the difference in antibody titers
against both vaccine viruses was most pronounced in VN and NI
assays, and minimal in the HI assay. Previous studies with
inﬂuenza as well as HIV indicate that the prime-boost response
may be affected by the order and timing of immunizations and
by the vaccine formulations.16–18, 20, 38, 44, 45 Yet the key question
remains whether the concept applies to any combination of
sufﬁciently distant H3N2 viruses. Afﬁrmative results come
from studies using different combinations of inactivated,
adjuvanted H1N1 or H5 inﬂuenza viruses, and different
immunization schemes, in humans, zoo birds and laboratory
animals.17, 18, 20, 38, 46, 47 These studies mostly used subunit
vaccines and the human-approved oil-based adjuvants MF59 and
AS03, which appear to be critical for the efﬁcacy of the prime-
boost regimes. Both adjuvants have been shown to drive the
expansion of memory B cells that can recognize variant inﬂuenza
strains not included in the original vaccine.17, 38, 46 The Emulsigen®
adjuvant used in our study is also an oil-in-water emulsion and will
presumably have similar effects.
Other researchers have reported enhanced lung lesions after
vaccination of pigs with whole inactivated SIV and challenge with
heterologous strains of the same subtype.25 This so-called
“vaccine-associated enhanced respiratory disease” is characterized
by increased gross lung lesions and microscopic lung and tracheal
lesion scores in the vaccinated pigs as compared to unvaccinated
challenge controls. It has been attributed to non-neutralizing
virus-binding antibodies and has raised concern about the use of
inactivated SIV vaccines and the design of universal inﬂuenza
vaccines for humans.48 The studies describing VAERD generally
used the more aggressive intratracheal inoculation route, whereas
we used intranasal inoculation. In any case it is reassuring that
none of the vaccine groups in our study showed enhanced
respiratory tract pathology.
In summary, we have demonstrated that priming and booster
vaccinations with antigenically very distinct, geographically
separated H3N2 SIV lineages can induce protection against both
and increase cross-cluster serologic reactivity. It remains to be
examined whether our ﬁndings extend to other combinations of
Table 3. Comparison of NI antibody titers against heterologous H3N2 and H1N2 inﬂuenza viruses in pigs of different vaccine groups
Geometric mean antibody titer (no. of pigs with detectable titers)
1° G08 PA10 G08 – G08+PA10
2° G08 PA10 PA10 G08+PA10 G08+PA10
Virus lineage/strain n= 6 n= 6 n= 6 n= 6 n= 4
Eu swine N2
Sw/Gent/2008 (H3N2) 1140 (6) 36 (4) 806 (6) 10 320 (4)
Sw/Gent/2012 (H1N2) 22 (3) 50 (5) 160 (6) 10 95 (4)
N A swine H3N2
Sw/TX/1998 (hu ’95-’96)* 11 (1) 25 (3) 57 (5) 10 34 (4)
Sw/PA/2010 (hu ’01-’02) 11 (1) 806 (6) 143 (6) 10 381 (4)
A/IN/2011 (hu ’01-’02) 10 453 (6) 57 (5) 10 320 (4)
Sw/IA/2011 (hu ’95-’96) 20 (4) 80 (6) 45 (6) 10 67 (4)
Human H3N2
A/Perth/2009 10 11 (1) 13 (1) 10 10
A/Victoria/2011 10 10 11 (1) 10 10
1°, 2°: Virus strains used for ﬁrst and second vaccination; Antibody titers were determined 2 weeks after the last vaccination (day 42); See table 1 for full virus
names, *origin of the NA indicated between brackets, hu= human seasonal H3N2 inﬂuenza virus; n= number of pigs examined per group Sera were tested at
an initial dilution of 1:20, those that were negative were assigned a titer of 10
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antigenically divergent H3N2 viruses, or what is the optimal
genetic distance between viruses, and whether it is possible to
induce a pan-H3N2 protection against past and future strains of
both swine and humans. Ideally, the heterologous H3N2 boost
would eliminate the need for two doses of bivalent H3N2 vaccine
and thus reduce the total amount of traditional SIV vaccine
needed by half and production costs by 25–30%.
MATERIALS AND METHODS
Vaccine preparation
G08 is representative of the European H3N2 SIV lineage, it was isolated
from an outbreak of acute respiratory disease in fattening pigs in East
Flanders, Belgium. PA10 is a cluster IV North American H3N2 SIV and was
obtained from the US Department of Agriculture (USDA) swine inﬂuenza
repository held at the National Veterinary Service Laboratories.
Virus stocks were generated by inoculation of Madin-Darby Canine
Kidney (MDCK, ATCC CCL-34) cells with 1 ml of virus (approx. 106.3 TCID50
per ml, ﬁrst passage in MDCK cells) in a volume of 10ml minimal essential
medium containing supplements (2 mM L-glutamine, 1 mg/ml lactalbumin,
100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamycin and 2
μg/ml trypsin) in T75 ﬂasks for 2 h at 37 °C, 5% CO2. Subsequently, fresh
medium was added and the cells were further incubated for at least 24 h or
until 40–50% cytopathogenic effect was observed. After one freeze-thaw
cycle, medium containing virus was clariﬁed by centrifugation (2 × 10min,
1831 g) and stored at −70 °C in 10ml aliquots. Vaccine virus stocks had a
titer of 108.3 TCID50 per ml. MDCK cells were free of Mycoplasma
contamination in a PCR detection kit (Sigma-Aldrich, St. Louis, MO, USA,
MP0035).
For ultraviolet light (UV) inactivation, 10 ml aliquots of virus were
thawed, placed in 60mm Petri dishes to a ﬂuid depth of 5 mm and
exposed to 120 J/cm2 from a UV source (Ultra-Violet Products Ltd.,
Cambridge, UK) for 10min. The dishes were placed on ice at a distance of
10 cm from the light source. Loss of viral infectivity was conﬁrmed by two
serial passages in MDCK cells. One milliliter aliquots of inactivated virus
were stored at −70 °C for later analysis in a standard HA assay with turkey
erythrocytes.49 HA titers were 2560 hemagglutinating units (HAU) per ml
before and after inactivation. Each 2ml vaccine dose contained 256 HAU of
inactivated G08 and/or PA10 virus diluted in phosphate-buffered saline
(PBS) and 20% commercial oil-in-water adjuvant (Emulsigen®, MVP
Laboratories, NE, USA). The inactivation method, adjuvant and antigen
dose had previously been shown to be appropriate for immunization of
pigs against SIVs.4, 25, 48
Experimental design and evaluation of protection against
challenge
Sixty-ﬁve 3-week-old conventional pigs which were free of inﬂuenza A
virus antibodies were divided into six groups (Table S2) and vaccinated
intramuscularly at 4 and/or 8 weeks of age. A mock-vaccinated challenge
control group (n = 12) received two administrations of PBS with adjuvant.
Two homologous prime-boost groups received two administrations of G08
(n = 12) and PA10 (n = 11) respectively. The heterologous prime-boost
group (n = 14) was primed with G08 and boosted with heterologous PA10
vaccine. Two bivalent vaccine groups were vaccinated with a combination
vaccine containing both G08 and PA10 at the age of 8 weeks only (n = 12)
or at 4 and 8 weeks (n = 4). Four additional pigs served as unvaccinated
unchallenged controls to assess histological characteristics of the
respiratory tract of healthy pigs of the same cohort. Animals were
randomly assigned to experimental groups. Sample size was calculated to
allow a signiﬁcance of P < 0.05 and 80% power.
One month after the booster vaccination all pigs, except unvaccinated
unchallenged controls, were challenged intranasally with 107 TCID50 SIV.
Half of the pigs in each group were challenged with G08 and half with
PA10. Each vaccination-challenge group was housed in a separate BSL2 +
isolation room. One pig in the G08 homologous prime-boost group died
from reasons unrelated to the experiment in the week before challenge,
leaving 11 pigs for challenge in this group. Three days post challenge all
pigs were euthanized to evaluate virus titers in 20% tissue homogenates of
the nasal mucosa, trachea and three different lung samples representing
the entire lung, as well as (histo)pathological lesion scores of the trachea
and lungs.
Virus titrations were performed in MDCK cells.50 Lesions of the lung and
trachea were analyzed and scored as described by Vincent et al.25
Laboratory analyses were performed blinded. All experiments were
performed at the Faculty of Veterinary Medicine, Ghent University, and
approved and supervised by its Ethical Committee.
Serum antibody responses
Serum samples were collected immediately before the priming and
booster vaccinations and 2 and 4 weeks after the booster (weeks 0, 4, 6, 8)
to determine HI, VN, and NI antibody titers against G08 and PA10. All sera
were examined in HI and VN assays, and 4 to 8 sera per group in NI assays.
Two weeks after the last vaccination 4 to 6 sera per group were analysed
for HI, VN, and NI titers against swine and human inﬂuenza viruses with an
antigenically distinct H3 or N2 (Tables 1–3). HA1, HA2, and NA sequences
of these viruses were downloaded from GenBank and % aa identity with
the sequences of the vaccine strains was determined with the MegAlign
program and DNASTAR 5.01 software. Amino acid differences at putative
antigenic sites of the HA1 and NA, as deﬁned by others,11, 22–24 were
identiﬁed by alignment using MEGA 6.06 software. The same sera were
examined in an ELISA for antibodies against the H3 HA stalk of A/Perth/16/
2009. Sera from the mock-vaccinated control, heterologous prime-boost
and both homologous prime-boost groups were tested for HI and VN titers
against European avian-like H1N1 (sw/Gent/28/2010) and human-like
H1N2 (sw/Gent/26/2012) SIVs, and low pathogenic H4N1 (mallard/Alberta/
47/1998), H4N6 (duck/Belgium/06936/2005) and H7N1 (chicken/Italy/1067/
1999) avian inﬂuenza viruses.
HI, VN, and NI assays were performed according to standard
procedures.49–51 For A/Perth/16/2009 and A/Victoria/361/2011, however,
we used guinea pig instead of turkey red blood cells in the HI assay52 and
MDCK-SIAT1 cells in the VN assay.53 Antibody titers were expressed as the
reciprocal of the highest serum dilution that inhibited hemagglutination or
virus replication, or that gave a 50% inhibition of NA activity. Sera were
tested separately and in duplicate, at an initial dilution of 1:10 or 1:20 in HI
and NI, and 1:2 or 1:16 in VN assays.
ELISAs were performed as described before31 with a secondary
peroxidase-labeled rabbit anti-pig IgG antibody (Sigma-Aldrich, A5670)
instead of anti-human IgG and a serum starting dilution of 1:100. Two
substrates were used: recombinant cH5/3 HA protein with the stalk domain
of A/Perth/16/2009 (H3N2) and the head domain of A/Vietnam/1203/2004
(H5N1) and trimeric recombinant head-only protein from A/Vietnam/1203/
2004, both produced in insect cells.54, 55 Optical density values measured
with the head-only construct were subtracted from the values measured
with the cH5/3 protein. Endpoint titers were calculated using the average
of blank wells plus 3 standard deviations as cut off.
ELISPOT analysis of antibody secreting cells
Heparinized whole blood for isolation of PBMC56 was collected at the time
of the last vaccination and 7 days later from four pigs per group, except for
the bivalent vaccine (2x) group. An ELISPOT assay to determine IgG ASC
speciﬁc for G08, PA10 and IN11 was performed as described by Kitikoon
et al.56 Brieﬂy, 96-well ELISPOT ﬁlter plates (MAIPS4510, Millipore Corp.,
MA, USA) were coated overnight with 200 HAU per well of live puriﬁed
inﬂuenza virus. Freshly isolated PBMC (5 × 105 cells per well) were
dispensed into duplicate wells. After 18 h incubation (37 °C, 5% CO2)
mouse anti-swine IgG monoclonal antibody (clone 27.8.1, CVI Lelystad, The
Netherlands) was added followed by HRP-labeled goat anti-mouse
immunoglobulins (Dako, Glostrup, Denmark, P0447). ASC were visualized
using the TMB Liquid Substrate System for Membranes (Sigma-Aldrich)
and counted with an ELISPOT plate reader. Non-speciﬁc spots detected in
wells coated with mock-infected MDCK cell medium were subtracted from
the counts of inﬂuenza-speciﬁc ASC.
Statistical analysis
Antibody titers against the vaccine strains, numbers of ASC and lesion
scores were compared between groups using the Kruskal-Wallis test.
Analysis of variance (ANOVA) was used to compare virus titers, and Fisher’s
exact test for virus isolation rates and numbers of pigs with lesions.
Kruskal-Wallis was followed by Dunn’s test, and ANOVA by Dunnett’s test.
Samples that tested negative in serological assays were assigned a value
corresponding with half of the minimum detectable antibody titer.
Samples that tested negative for virus were given a value of 0.85 log10
TCID50. Spearman’s rank correlation coefﬁcient was used to assess the
relationship between virus titers and lesion scores.
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